OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) Files An 8-K Other Events

OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) Files An 8-K Other Events
Item 8.01. Other Events.

Story continues below

OWC Pharmaceutical Research Corp. (the “Registrant”), is filing with this Form 8-K, a Press Release, a copy of which is attached hereto as Exhibit 99.1 and is dated and will be published tomorrow, December 21, 2017. The Registrant’s Press Release announces that the Registrant received a new permit from the Israel Medical Cannabis Agency [MCA] to proceed with the safety study of their oral disintegrating tablet. The study protocol will be submitted to the Institutional Review Board [IRB] at a leading Israeli academic hospital in the coming weeks. The study is scheduled to start in Q2 2018.

Item 9.01 Financial Statements and Exhibits.

(a) The following documents are filed as exhibits to this report on Form 8-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.


OWC Pharmaceutical Research Corp. Exhibit
EX-99.1 2 ex99-1.htm   EXHIBIT 99.1   OWC Pharmaceutical Research Corp. [OTCQB: OWCP] Announces Update on its Proprietary Medical Cannabis Sublingual Tablet   In December 2017,…
To view the full exhibit click here

About OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP)

OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.

An ad to help with our costs